NCT02293213 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Eisenberg DL, Stika C, Desai A, Baker D, Yost KJ
Providing contraception for women taking potentially teratogenic medications: a survey of internal medicine physicians' knowledge, attitudes and barriers. J Gen Intern Med. 2010 Apr;25(4):291-7. doi: 10.1007/s11606-009-1215-2. Epub 2010 Jan 20.
Jones J, Mosher W, Daniels K
Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995. Natl Health Stat Report. 2012 Oct 18;(60):1-25.
Santucci AK, Gold MA, Akers AY, Borrero S, Schwarz EB
Women's perspectives on counseling about risks for medication-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2010 Jan;88(1):64-9. doi: 10.1002/bdra.20618.
Steinkellner A, Chen W, Denison SE
Adherence to oral contraception in women on Category X medications. Am J Med. 2010 Oct;123(10):929-934.e1. doi: 10.1016/j.amjmed.2010.05.009.
Trussell J
Contraceptive failure in the United States. Contraception. 2011 May;83(5):397-404. doi: 10.1016/j.contraception.2011.01.021. Epub 2011 Mar 12. Review.

Utilizing Electronic Medical Record Referrals for Teratogen and Contraceptive Counseling for Women Taking Category D or X Medications: A Randomized Controlled Trial

Details for clinical trial NCT02293213

Clinical trial NCT02293213 - References